Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands

Table 4

Results presenting outpatient chemotherapy visits and data relating to AEs and hospital visits relating to AEs.

	Outpatient visits		Hospitalizations, outpatient visits, and number of total AEs
Clinical practice	Outpatient chemotherapy visits total	Hospitalizations due to short-term grade III/IVs AEs total	Outpatient visits due to short-term AE total	Number of AE total (short term and long term)
Oncotype DX test	4,937	97	482	505
No genomic test	18,286	361	1,784	1,869
MammaPrint	9,875	195	964	1,009
Difference between Oncotype DX test vs. no genomic test	-13,349	-264	-1,303	-1,364
Difference between Oncotype DX test vs. MammaPrint	-4,937	-97	-482	-505

Abbreviation: AEs = adverse events.